Research programme: immunotherapeutic antibodies - GlaxoSmithKline/InNexus

Drug Profile

Research programme: immunotherapeutic antibodies - GlaxoSmithKline/InNexus

Latest Information Update: 25 May 2007

Price : $50

At a glance

  • Originator GlaxoSmithKline; InNexus Biotechnology
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Small cell lung cancer

Most Recent Events

  • 07 Nov 2005 Preclinical trials in Small cell lung cancer in USA (unspecified route)
  • 17 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top